Nick Knudsen

825 total citations
12 papers, 286 citations indexed

About

Nick Knudsen is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Immunology. According to data from OpenAlex, Nick Knudsen has authored 12 papers receiving a total of 286 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Radiology, Nuclear Medicine and Imaging, 6 papers in Oncology and 3 papers in Immunology. Recurrent topics in Nick Knudsen's work include Monoclonal and Polyclonal Antibodies Research (6 papers), Radiopharmaceutical Chemistry and Applications (4 papers) and HER2/EGFR in Cancer Research (4 papers). Nick Knudsen is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (6 papers), Radiopharmaceutical Chemistry and Applications (4 papers) and HER2/EGFR in Cancer Research (4 papers). Nick Knudsen collaborates with scholars based in United States and Italy. Nick Knudsen's co-authors include Sandra L. Biroc, Lillian Skidmore, Yi Gu, Robin Marsden, Sulan Yao, Snezana Milutinovic, Wayne Yu, Sukumar Sakamuri, Feng Tian and Anthony Manibusan and has published in prestigious journals such as Angewandte Chemie International Edition, PLoS ONE and Cancer Research.

In The Last Decade

Nick Knudsen

12 papers receiving 280 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nick Knudsen United States	7	194	169	94	35	31	12	286
Kirsten Achilles Poon United States	6	180 0.9×	142 0.8×	74 0.8×	23 0.7×	14 0.5×	6	278
Veena S. John United States	7	142 0.7×	88 0.5×	102 1.1×	24 0.7×	11 0.4×	26	268
Aimee Fourie-O’Donohue France	9	180 0.9×	187 1.1×	103 1.1×	26 0.7×	31 1.0×	10	279
Leanne Lanieri United States	7	179 0.9×	137 0.8×	86 0.9×	10 0.3×	29 0.9×	17	286
Komal Mandleywala United States	10	115 0.6×	159 0.9×	106 1.1×	52 1.5×	30 1.0×	16	345
Brandon M. Bordeau United States	10	256 1.3×	201 1.2×	101 1.1×	48 1.4×	7 0.2×	15	380
Daniel Young United States	10	105 0.5×	73 0.4×	99 1.1×	55 1.6×	11 0.4×	18	257
Camilla Hofström Sweden	9	165 0.9×	274 1.6×	124 1.3×	33 0.9×	13 0.4×	16	350
Christian Pellegrino Switzerland	9	197 1.0×	98 0.6×	154 1.6×	22 0.6×	54 1.7×	21	309

Countries citing papers authored by Nick Knudsen

Since Specialization

Citations

This map shows the geographic impact of Nick Knudsen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nick Knudsen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nick Knudsen more than expected).

Fields of papers citing papers by Nick Knudsen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nick Knudsen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nick Knudsen. The network helps show where Nick Knudsen may publish in the future.

Co-authorship network of co-authors of Nick Knudsen

This figure shows the co-authorship network connecting the top 25 collaborators of Nick Knudsen. A scholar is included among the top collaborators of Nick Knudsen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nick Knudsen. Nick Knudsen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Skidmore, Lillian, David Mills, Nick Knudsen, et al.. (2024). Preclinical Characterization of ARX517, a Site-Specific Stable PSMA-Targeted Antibody–Drug Conjugate for the Treatment of Metastatic Castration-Resistant Prostate Cancer. Molecular Cancer Therapeutics. 23(12). 1842–1853. 6 indexed citations

Azzinaro, Paul A., Peter C. Canning, Lillian Skidmore, et al.. (2024). Prophylactic treatment with PEGylated bovine IFNλ3 effectively bridges the gap in vaccine-induced immunity against FMD in cattle. Frontiers in Microbiology. 15. 1360397–1360397. 1 indexed citations

Mills, David, Erica M. Wood, Keith Tatsukawa, et al.. (2024). Abstract 6352: Preclinical discovery of ARX622: A site-specific, TLR7 agonist, HER2-targeted immune-stimulatory antibody drug conjugate for treatment of multiple solid tumor types. Cancer Research. 84(6_Supplement). 6352–6352. 1 indexed citations

Yu, Wayne, Mysore P. Ramprasad, Manoj K. Pal, et al.. (2023). Analytical comparability to evaluate impact of manufacturing changes of ARX788, an Anti-HER2 ADC in late-stage clinical development. PLoS ONE. 18(7). e0284198–e0284198. 4 indexed citations

Skidmore, Lillian, David Mills, Nick Knudsen, et al.. (2023). Abstract 3997: Preclinical characterization of ARX517, a next-generation anti-PSMA antibody drug conjugate for the treatment of metastatic castration-resistant prostate cancer. Cancer Research. 83(7_Supplement). 3997–3997. 3 indexed citations

Kang, Mingchao, Andy Beck, Jay A. Nelson, et al.. (2022). Abstract 5616: Tumor-targeted immune activation via a site-specific TLR7-agonist antibody-drug conjugate. Cancer Research. 82(12_Supplement). 5616–5616. 3 indexed citations

Skidmore, Lillian, Sukumar Sakamuri, Nick Knudsen, et al.. (2020). ARX788, a Site-specific Anti-HER2 Antibody–Drug Conjugate, Demonstrates Potent and Selective Activity in HER2-low and T-DM1–resistant Breast and Gastric Cancers. Molecular Cancer Therapeutics. 19(9). 1833–1843. 121 indexed citations

Kern, Jeffrey C., Rena Zhang, Linda Liang, et al.. (2016). Novel Phosphate Modified Cathepsin B Linkers: Improving Aqueous Solubility and Enhancing Payload Scope of ADCs. Bioconjugate Chemistry. 27(9). 2081–2088. 64 indexed citations

Humphreys, Robin, et al.. (2015). Abstract 639: Site specific conjugation of ARX-788, an antibody drug conjugate (ADC) targeting HER2, generates a potent and stable targeted therapeutic for multiple cancers. Cancer Research. 75(15_Supplement). 639–639. 27 indexed citations

10.

Kularatne, Sumith A., V. Deshmukh, Marco Gymnopoulos, et al.. (2013). Recruiting Cytotoxic T Cells to Folate‐Receptor‐Positive Cancer Cells. Angewandte Chemie International Edition. 52(46). 12101–12104. 36 indexed citations

11.

Kularatne, Sumith A., V. Deshmukh, Marco Gymnopoulos, et al.. (2013). Recruiting Cytotoxic T Cells to Folate‐Receptor‐Positive Cancer Cells. Angewandte Chemie. 125(46). 12323–12326. 9 indexed citations

12.

Knudsen, Nick, et al.. (1984). Why bother with stop-smoking education for lung cancer patients?. PubMed. 11(3). 30–3. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact